Alopecia Areata
Alopecia areata is an autoimmune condition in which the immune system targets hair follicles, producing characteristic patches of complete hair loss. It is biologically and clinically distinct from androgenetic alopecia (pattern hair loss), and the treatments are different. People with alopecia areata are not "going bald" in the pattern sense; they are dealing with an immune-driven process that can come, go, recur, or progress, depending on the case.
Alopecia areata affects roughly 2 percent of the population over a lifetime (Mirzoyev et al., J Invest Dermatol, 2014). It can begin at any age, but onset most often falls in childhood, adolescence, or young adulthood. Severity varies widely between people, and often within the same person over time.
How it appears
The most common presentation is one or more sharply demarcated, round or oval patches of hair loss on the scalp, often roughly the size of a coin. The skin within the patch is smooth and looks normal, without redness, scaling, or scarring (this is one of the features that helps tell it apart from scarring alopecias). The hair around the edge of an active patch sometimes shows a characteristic "exclamation mark" pattern, where the hair is narrower at the scalp than at the tip and breaks off easily.
The condition can be limited to a single patch and resolve on its own, or it can progress to larger and more numerous patches. Less commonly, it can extend to:
- Alopecia totalis: complete or near-complete loss of scalp hair
- Alopecia universalis: loss of all body hair, including eyebrows, eyelashes, and body hair
- Ophiasis pattern: band-like loss around the lower scalp from ear to ear
- Diffuse alopecia areata: a less common pattern producing scalp-wide thinning rather than patches
Onset is often surprisingly fast. Patients commonly notice a fully formed bald patch over the course of days or a couple of weeks rather than the slow drift of pattern hair loss.
What's happening biologically
The follicle is normally an "immune privileged" site, meaning the immune system is held back from interacting with it. In alopecia areata, that privilege breaks down. T cells infiltrate the follicle, targeting it for attack and disrupting the growth phase. Affected follicles shift abruptly into the resting and shedding phases, but the follicle itself remains intact, which is why hair can regrow if the immune attack settles.
The condition is associated with other autoimmune conditions in some patients, including thyroid disease (especially Hashimoto's, which can also cause thyroid-related shedding in women), vitiligo, type 1 diabetes, and lupus. A family history of alopecia areata or other autoimmune disease raises risk.
Nail changes
A subset of patients with alopecia areata develop visible changes in the fingernails or toenails: small pinpoint pits, ridging, roughness, or longitudinal striations. These changes can precede, accompany, or follow the hair patches. They are a useful clinical clue when the diagnosis is uncertain.
How it differs from pattern hair loss
| Feature | Alopecia areata | Pattern hair loss |
|---|---|---|
| Pattern | Round patches, sometimes scalp-wide | Temple recession, crown thinning, widening part |
| Onset | Days to a few weeks | Years |
| Skin | Smooth, normal-looking within patches | Normal scalp, follicles miniaturized |
| Mechanism | Autoimmune attack on follicles | Hormonal sensitivity, genetic |
| Regrowth potential | Often regrows spontaneously | Does not regrow without treatment |
| Treatment | Anti-inflammatory, immune-modulating | Anti-androgen, follicle-stimulating |
The mechanisms are unrelated, but the two conditions can coexist in the same person, which sometimes makes the picture less clean than the table suggests.
Course and prognosis
The natural history of alopecia areata is hard to predict for any individual patient. Common outcomes:
- A single patch that fully regrows within six to twelve months, sometimes without any treatment
- Recurrent patches that come and go over years, with regrowth between episodes
- Progression to more extensive disease, including alopecia totalis or universalis
Factors associated with a more difficult course include onset in early childhood, longer duration of an active episode, extensive loss at presentation, and family history of more severe alopecia areata. The ophiasis pattern in particular tends to be more resistant to treatment.
Regrowth, when it happens, often starts as fine, white or unpigmented hairs that gradually darken over months as melanocyte function recovers.
Diagnosis
Alopecia areata is usually diagnosed clinically by a dermatologist based on the appearance of the patches and the patient's history. A scalp biopsy is sometimes done when the pattern is atypical. Trichoscopy (a magnified examination of the scalp) can reveal characteristic features like exclamation-mark hairs, yellow dots, and black dots.
Lab tests are not required for diagnosis, but a dermatologist may screen for associated autoimmune conditions (thyroid function, vitamin D, sometimes others) depending on the picture.
Current treatment options
Treatment depends on the extent and pace of the disease, the patient's age, and how the patient is doing emotionally. Options that a dermatologist may consider include:
- Topical corticosteroids, applied to affected patches to reduce immune activity locally
- Intralesional corticosteroid injections (small steroid injections into the patch), commonly used for limited disease
- Topical minoxidil as an adjunct to stimulate regrowth, used alongside other treatments rather than as primary therapy
- Contact immunotherapy (using a sensitizing chemical to provoke a controlled local immune reaction that displaces the alopecia areata reaction), used in specialty centers for more extensive disease
- Oral corticosteroids, occasionally used for rapidly progressing disease, though long-term use is limited by side effects
- JAK inhibitors: a class of oral medications that block specific immune-signaling pathways. Baricitinib received FDA approval in 2022 for severe alopecia areata in adults, the first systemic treatment specifically approved for this condition (King et al., N Engl J Med, 2022). Ritlecitinib was approved in 2023 for severe alopecia areata in patients 12 and older. Other JAK inhibitors are in clinical use or development.
Treatment selection, dosing, and monitoring for these options sit firmly in dermatology, not telehealth. JAK inhibitors in particular require pre-treatment screening and ongoing lab monitoring.
Curekey's scope
Curekey's telehealth pathway is built around pattern hair loss, and the treatments we offer (oral finasteride, oral and topical minoxidil) are appropriate for that condition. Alopecia areata is a different process and is not managed through our pathway. If your hair loss is in well-defined patches with smooth skin, has appeared rapidly, or comes with nail changes, an in-person dermatologist visit is the right next step.
For patients who have both alopecia areata managed by a dermatologist and pattern hair loss, the two can be addressed in parallel, and a Curekey clinician can support the pattern hair loss side when medically appropriate.
When to see a dermatologist
See a dermatologist for evaluation if you are noticing:
- One or more well-defined patches of complete hair loss, with smooth, normal-looking skin
- Sudden hair loss appearing over days or a few weeks
- Patchy loss of eyebrow or eyelash hair
- New pitting or ridging of the fingernails or toenails alongside hair loss
- Hair loss in a child or teenager that is not gradual or patterned
For pattern hair loss in adults, a Curekey clinician can help you understand options and whether treatment is appropriate when medically appropriate. Start a free assessment, or read how it works first.
